Message from the President and CEO
NASDAQ: 2.237
TSX: 2.84
FR
-
EN
About
Our history
Board of Directors
Leadership Team
Scientific Consultants and Advisors
Awards
COVID 19
Commercialized products
Trogarzo®
EGRIFTA®
EGRIFTA SV®
Product Pipeline
Investors
Overview
Investor Presentations
News
Financial Reports and Public Filings
Corporate Governance
Analysts
FAQ
Careers
Contact
Contact information
Email alerts
RSS Feed
Recherche
FR
-
EN
About
Our history
Board of Directors
Leadership Team
Scientific Consultants and Advisors
Awards
COVID 19
Commercialized products
Trogarzo®
EGRIFTA®
EGRIFTA SV®
Product Pipeline
Investors
Overview
Investor Presentations
News
Financial Reports and Public Filings
Corporate Governance
Analysts
FAQ
Careers
Contact
Contact information
Email alerts
RSS Feed
Recherche
FR
-
EN
May 01, 2014
Theratechnologies regains rights to EGRIFTA (tesamorelin for injection) in the United States
Download press release
